Science Links Japan | Journal of Clinical Therapeutics & Medicines

List of Jounal Titles

A to Z index of Journal Title. Choose a letter.

A/ B/ C/ D/ E/ F/ G/ H/ I/ J/ K/ L/ M/ N/ O/ P/ Q/ R/ S/ T/ U/ V/ W/ X/ Y/ Z/ 0/ 1/ 2/ 3/ 4/ 5/ 6/ 7/ 8/ 9

Journal of Clinical Therapeutics & Medicines

Stratesgies for Successful Clinical Development in Japan.
How to manage Two Site/One Protocol Studies. Comments on TS/OP Studies.
How to manage Two Site/One Protocol Studies. Practical Issues.
2
Phase I Clinical Study of SND919 (Pramipexole) Tablets. 1. Single Dose Study.
Phase I Clinical Study of SND919 (Pramipexole) Tablets. 2. Multiple Dose Study.
Early Phase II study of SND919 (Pramipexole) Tablets in Parkinson's disease.
4
A randomized Comparison of Ketoconazole Lotion and Ketoconazole Cream for the Treatment of Seborrheic Dermatitis-R41400-L Clinical Research Group for Seborrheic Dermatitis-
Pharmacokineties of Pitavastatin (NK-104) Administered for 7-days to Volunteers with Fatty Liver-Pharmacokinetics and Safety of Pitavastatin Administered 2mg Daily for 7-days to 12 Volunteers, 6 with Fatty Liver, 6 Normal-
The Drug-drug Interactions of Pitavastatin (NK-104), a Novel HMG-CoA Reductase Inhibitor and Cyclosporine
5
Comparison of Efficacy between Insulin Glargine and NPH Human Insulin in Type 1 Diabetes Patients undergoing Intensive Insulin Treatment-Phase II/ III Clinical Studies in Japan-
Efficacy and Safety of Insulin Glargine in Concurrent Use with Oral Hypoglycemic Agents for the Treatment of Type 2 Diabetic Patients
Efficacy and Safety of Insulin Glargine in the Long-term Treatment of Type 2 Diabetic Patients
Influence of Insulin Glargine and NPH Human Insulin on QOL in Intensive Insulin Treatment for Type 1 Diabetic Patients
A Dose-response Study of Salmeterol Xinafoate Dry Powder by Single Administration for Adult with Bronchial Asthma-Randomized Double-blind, Cross Over Study-
6
Phase I Clinical Study of a Phosphate binder, PB-94 (Sevelamer Hydrochloride)-A Single Administration-
Phase I Clinical Study of a Phosphate binder, PB-94 (Sevelamer Hydrochloride)-Repeated Administration-
Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis-Phase III Double-blinded Comparison with Vehicle Ointment-
Long-term Study of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis
Clinical Pharmacokinetic Study of Talion Tablet (Bepotastine Besilate) in Nephropathic Patients (Post-Marketing Clinical Trial)
Changes in QOL (SF-36) Scores of Patients with Vibration Syndrome before and after Administration of LipoPGE1 Preparation (Liple)-Focusing on Comprehensive Health-related QOL (SF-36)-
Investigation on the Efficacy and Safety of Low-stimulus, Hypoallergenic New Sunscreen Product
7
Phase I Clinical Study of Biphasic Insulin Aspart 30 (BIAsp30)-The Safety, Pharmacokinetics and Pharmacodynamics of BIAsp30 compared to Biphasic Human Insulin-
Phase III Open Study of 1% Nadifloxacin Ointment for Skin infected Diseases
Effect of Maxacalcitol on the Treatment of Psoriasis Vulgaris-A Comparative study of Monotherapy of Maxacalcitol Ointment and Concurrent use of Maxacalcitol and Dexamethasone Propionate Ointment-
Economic Analysis of Antihypertensive Agents in Treating Patients with Essential Hypertension
8
4 Weeks Trial with Biphasic Insulin Aspart 30 in Type 2 Diabetes (NIDDM): Phase II Clinical Trial
Comparison of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 after 48 Weeks of Treatment in Type 2 Diabetes: Phase III Clinical Trial
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 30 in Healthy Japanese Subjects
Effect on Postprandial Hyperglycemia by Combined Administration of Mulberry Leaves Concentrated Dried Tablet and Onion concentrated Dried Tablet in Diabetes Patients
9
Clinical Evaluation of CS-866 (Olmesartan Medoxomil), a novel Angiotensin II Receptor Antagonisit, in Patients with Mild-to-moderate Essential Hypertension-Pre-pilot Phase II Study-
Clinical Evaluation of CS-866 (Olmesartan Medoxomil), a novel Angiotensin II Receptor Antagonist, in Patients with Mild-to-moderate Essential Hypertension-Pilot Phase II Study-
The Optimal Dose of CS-866 (Olmesartan Medoxomil), a novel Angiotensin II Receptor Antagonist, in Patients with Mild-to-moderate Essential Hypertension-Late Phase II Study-
Drug Use Investigation of Ebastine in Pediatric Patients with Allergic Rhinitis, Urticaria and Skin Disorder Accompanied with Itch.
10
The Efficacy and Safety of Long-term Administration of CS-866 (Olmesartan Medoxomil), a novel Angiotensin II Receptor Antagonist, in the Treatment of Mild to Moderate Essential Hypertension-A Long-term Phase II Clinical Study-
Pharmacokinetics of Single Oral Dosage of CS-866 (Olmesartan medoxomil), Angiotensin II Receptor Antagonist, Planned to be Clinically Used
Pharmacokinetics of Repeated Oral Dosages of CS-866 (Olmesartan medoxomil), Angiotensin II Receptor Antagonist, Planned to be Used Clinically
Post-marketing Special Survey of the Efficacy and Safety of Gliclazide (Glmicron) on Type 2 Diabetes Patients with Mild Disease Severity or Being Treated Only with an Alpha Glucosidase Inhibitor without Sufficient Efficacy
Points to Consider for Development and Introduction of Electronic Data Capture System in Japan and Its Future Perspectives with Respect to the Current Situation
11
Pharmacokinetics of 40mg Dose of CS-866, an Angiotensin II Receptor Antagonist, in Essential Hypertensive Patients
Influence of Food Intake on Pharmacokinetics of CS-866 (Olmesartan Medoxomil), an Angiotensin II Receptor Antagonist
Comparison of Pharmacokinetics of CS-866 (Olmesartan Medoxomil), an Angiotensin II Receptor Antagonist, in Elderly and Non-elderly Subjects
Phase III Open-labeled Study of Epinastine Hydrochloride Dry Syrup in Pediatric Patients with Atopic Dermatitis - Evaluation of Safety for 3 Months Administration -
A Case Report of the Man whose Skin Erosion caused by Food Debris that Leaked from a Tracheotomy Hole was Improved by Fudostein
12
Investigation of Relationship between Pharmacokinetics and Antihypertensive Effect of CS-866 (Olmesartan Medoxomil) in Mild to Moderate Essential Hypertensive Patients